▁British 10.375
▁Bi 10.859375
ote 5.58203125
ch 4.43359375
▁Pl 7.56640625
c 5.91015625
, 6.23046875
▁a 4.86328125
▁leading 7.58203125
▁bi 5.6640625
ote 0.57861328125
chn 3.134765625
ology 0.335205078125
▁company 2.5234375
, 0.982421875
▁has 4.58203125
▁triumph 11.4375
ed 0.98486328125
▁in 2.25390625
▁its 3.521484375
▁quest 5.30078125
▁to 2.17578125
▁develop 5.21484375
▁a 1.91015625
▁ground 6.94140625
bre 1.1650390625
aking 0.1871337890625
▁cancer 7.953125
▁drug 3.5234375
, 2.025390625
▁Mar 10.59375
im 7.828125
ast 7.99609375
at 5.28125
. 2.564453125
▁Despite 8.2109375
▁its 2.744140625
▁success 3.37890625
▁in 1.3759765625
▁early 6.765625
▁clin 1.6572265625
ical 0.0087738037109375
▁tri 0.361572265625
als 0.0014543533325195312
, 0.288818359375
▁the 0.916015625
▁company 1.1611328125
▁faces 3.978515625
▁several 3.36328125
▁obst 2.765625
acles 0.0008587837219238281
▁on 4.31640625
▁its 0.859375
▁path 1.29296875
▁to 0.280029296875
▁transform 6.78125
ing 0.68408203125
▁this 4.0546875
▁potential 4.3984375
▁break 2.681640625
through 0.01444244384765625
▁into 0.69140625
▁a 0.33642578125
▁block 5.16796875
b 0.093994140625
uster 0.005672454833984375
▁drug 1.36328125
. 0.431640625
<0x0A> 1.060546875
Mar 4.24609375
im 2.828125
ast 0.06829833984375
at 0.00612640380859375
▁targets 5.3203125
▁an 3.193359375
▁en 1.68359375
zym 0.013885498046875
e 0.0107574462890625
▁known 2.611328125
▁as 0.1004638671875
▁metal 7.9765625
lo 0.1451416015625
prote 0.491943359375
ase 2.052734375
, 2.298828125
▁responsible 5.29296875
▁for 0.015380859375
▁reg 4.82421875
ulating 0.0853271484375
▁the 0.63623046875
▁growth 3.037109375
▁and 1.0205078125
▁spread 3.103515625
▁of 0.0927734375
▁cancer 0.7646484375
ous 2.2109375
▁cells 0.73291015625
. 0.31201171875
▁Enc 8.3203125
ou 0.60693359375
rag 0.0012712478637695312
ingly 1.0703125
, 0.031158447265625
▁initial 4.84765625
▁tri 2.736328125
als 0.0014667510986328125
▁have 1.4345703125
▁shown 0.73046875
▁prom 1.7548828125
ising 0.0001398324966430664
▁results 0.300048828125
▁in 1.55078125
▁in 3.765625
hib 0.061126708984375
iting 0.00927734375
▁the 0.75244140625
▁pro 4.13671875
gression 1.328125
▁of 0.058013916015625
▁various 4.5859375
▁solid 4.09765625
▁tum 0.210205078125
or 2.484375
▁types 0.7578125
. 1.138671875
▁The 2.23046875
▁drug 1.7421875
▁has 1.69140625
▁exhib 5.13671875
ited 0.0009636878967285156
▁the 3.345703125
▁ability 0.8154296875
▁to 0.016815185546875
▁restrict 6.77734375
▁tum 1.974609375
or 0.050384521484375
▁invasion 5.171875
▁and 0.92236328125
▁met 1.3876953125
ast 0.0009560585021972656
asis 0.0948486328125
, 1.18359375
▁offering 6.01953125
▁hope 1.56640625
▁for 0.8017578125
▁millions 6.76953125
▁of 0.1953125
▁patients 0.9609375
▁world 2.125
wide 0.006999969482421875
. 0.58056640625
<0x0A> 0.66357421875
However 1.81640625
, 0.006732940673828125
▁British 12.140625
▁Bi 1.62890625
ote 0.0010442733764648438
ch 1.4560546875
▁must 5.36328125
▁confront 5.21484375
▁hur 5.7890625
d 2.1576881408691406e-05
les 0.0182647705078125
▁to 2.375
▁gain 4.4921875
▁appro 2.3359375
val 0.0002841949462890625
▁for 0.95947265625
▁Mar 2.953125
im 0.00653839111328125
ast 0.02423095703125
at 0.002506256103515625
' 2.291015625
s 0.0016918182373046875
▁commercial 2.94140625
▁use 2.32421875
. 0.448486328125
▁First 2.4140625
, 0.350341796875
▁the 0.759765625
▁company 1.0302734375
▁must 0.51318359375
▁successfully 4.49609375
▁navigate 3.091796875
▁the 1.046875
▁rig 3.423828125
orous 0.078857421875
▁regul 1.5126953125
atory 0.0003554821014404297
▁process 1.037109375
▁to 2.21484375
▁demonstrate 3.658203125
▁not 7.98828125
▁only 0.1494140625
▁the 1.2119140625
▁drug 1.767578125
' 0.0144500732421875
s 0.00022292137145996094
▁effect 2.369140625
iveness 0.01108551025390625
▁but 1.3662109375
▁also 0.222412109375
▁its 0.6435546875
▁safety 0.146240234375
. 0.75732421875
▁The 3.0859375
▁company 1.4736328125
▁faces 4.76953125
▁the 3.005859375
▁challenge 0.70068359375
▁of 0.034698486328125
▁conduct 5.43359375
ing 0.0002014636993408203
▁more 5.73046875
▁extensive 2.482421875
▁clin 0.7841796875
ical 0.0002105236053466797
▁tri 0.093994140625
als 5.7220458984375e-06
▁to 0.84765625
▁meet 5.2734375
▁the 0.88818359375
▁string 2.423828125
ent 0.0008587837219238281
▁requirements 1.02734375
▁of 0.3583984375
▁regul 1.94921875
atory 0.2489013671875
▁authorities 1.130859375
. 0.88818359375
<0x0A> 1.2373046875
Add 2.92578125
itionally 0.0305328369140625
, 0.0013904571533203125
▁British 0.6455078125
▁Bi 0.0112457275390625
ote 0.0002913475036621094
ch 0.0382080078125
▁must 0.34033203125
▁address 2.888671875
▁concerns 3.248046875
▁surrounding 3.35546875
▁potential 3.32421875
▁side 0.63671875
▁effects 0.022613525390625
. 1.517578125
▁The 1.71484375
▁drug 1.01171875
▁has 1.51953125
▁demonstrated 2.60546875
▁m 5.875
ild 0.0191192626953125
▁g 4.89453125
astro 0.00522613525390625
int 0.004634857177734375
est 0.0008025169372558594
inal 0.00014102458953857422
▁issues 3.818359375
, 1.2939453125
▁such 2.123046875
▁as 0.004413604736328125
▁di 1.4677734375
arr 0.0006313323974609375
he 0.016082763671875
a 0.0005879402160644531
▁and 0.58447265625
▁n 0.65185546875
ause 3.635883331298828e-05
a 0.0007910728454589844
, 0.453125
▁which 1.833984375
▁require 4.6015625
▁further 3.00390625
▁investigation 1.626953125
. 0.85400390625
▁Mit 11.1015625
ig 0.01091766357421875
ating 0.0770263671875
▁these 0.5283203125
▁effects 3.77734375
▁will 1.3056640625
▁be 0.83349609375
▁essential 2.404296875
▁to 0.583984375
▁ensure 2.216796875
▁patient 1.6328125
▁well 4.91796875
- 0.21142578125
be 0.0010499954223632812
ing 1.609325408935547e-05
▁and 1.015625
▁gain 5.90625
▁accept 3.95703125
ance 0.004604339599609375
▁from 1.3349609375
▁regul 1.2587890625
ators 1.40625
▁who 7.06640625
▁prior 5.53125
it 0.00028204917907714844
ize 0.00823974609375
▁patients 3.841796875
' 0.533203125
▁safety 0.4892578125
▁and 3.384765625
▁quality 2.833984375
▁of 0.1221923828125
▁life 0.077880859375
. 0.2115478515625
<0x0A> 0.1253662109375
F 3.244140625
ur 0.296142578125
ther 0.0001475811004638672
▁challeng 3.853515625
es 0.0004715919494628906
▁emer 6.30859375
ge 0.057464599609375
▁in 2.10546875
▁the 0.92822265625
▁form 2.322265625
▁of 0.005924224853515625
▁market 3.5390625
▁competition 1.6025390625
. 0.515625
▁Despite 4.4140625
▁Mar 3.291015625
im 0.0036296844482421875
ast 0.00897979736328125
at 0.0013608932495117188
' 0.06451416015625
s 0.0002837181091308594
▁potential 2.064453125
, 1.4658203125
▁numerous 5.234375
▁existing 4.5546875
▁treat 2.751953125
ments 2.1576881408691406e-05
▁have 2.765625
▁established 4.05078125
▁themselves 2.51171875
▁in 1.3720703125
▁the 0.07025146484375
▁on 5.4375
col 0.049285888671875
ogy 0.0007643699645996094
▁field 3.201171875
. 0.59228515625
▁The 2.03125
▁drug 2.052734375
▁must 0.93115234375
▁prove 4.8515625
▁its 0.580078125
▁superior 2.654296875
ity 0.031402587890625
▁over 1.25
▁current 2.568359375
▁ther 1.556640625
ap 0.007534027099609375
ies 6.9141387939453125e-06
▁to 0.79736328125
▁persu 7.484375
ade 0.0006403923034667969
▁phys 1.5263671875
icians 0.003345489501953125
▁and 0.54052734375
▁patients 0.634765625
▁to 0.494384765625
▁switch 1.400390625
▁to 0.87353515625
▁Mar 2.720703125
im 0.00275421142578125
ast 0.009002685546875
at 0.0010824203491210938
. 0.43017578125
▁Ad 8.3828125
van 0.95263671875
c 1.146484375
ements 0.0002841949462890625
▁in 0.1864013671875
▁personal 4.5859375
ized 0.01947021484375
▁medicine 0.307861328125
▁and 1.3095703125
▁target 3.052734375
ed 0.018096923828125
▁ther 0.365234375
ap 0.1751708984375
ies 9.179115295410156e-06
▁present 4.16015625
▁considerable 5.39453125
▁obst 2.712890625
acles 0.0008554458618164062
▁in 3.74609375
▁establish 4.78125
ing 0.00018107891082763672
▁Mar 1.3603515625
im 0.0011196136474609375
ast 0.00467681884765625
at 0.0012149810791015625
▁as 0.65380859375
▁a 0.36962890625
▁true 5.984375
▁game 1.91015625
ch 3.69921875
anger 0.002964019775390625
. 0.5439453125
<0x0A> 0.199951171875
Fin 2.689453125
ally 0.0157623291015625
, 0.0013561248779296875
▁British 0.488037109375
▁Bi 0.00272369384765625
ote 6.842613220214844e-05
ch 0.005054473876953125
▁must 0.2431640625
▁strateg 6.9453125
ize 0.52490234375
▁efficient 8.3828125
▁manufact 2.52734375
uring 0.011871337890625
▁and 1.5419921875
▁distribution 0.48486328125
▁to 1.2373046875
▁achieve 3.515625
▁w 2.48046875
ides 0.00011861324310302734
p 0.0017948150634765625
read 0.0001176595687866211
▁ad 2.38671875
option 0.0017824172973632812
▁and 2.6015625
▁overcome 5.8984375
▁pr 6.10546875
icing 0.0031147003173828125
▁hur 2.392578125
d 0.0003414154052734375
les 0.000247955322265625
. 0.133544921875
▁The 1.2509765625
▁successful 6.8671875
▁production 4.1953125
▁and 0.91064453125
▁distribution 0.379638671875
▁of 0.06353759765625
▁Mar 0.560546875
im 0.00039196014404296875
ast 0.005035400390625
at 0.000682830810546875
▁on 7.296875
▁a 0.271240234375
▁large 0.896484375
▁scale 0.06524658203125
▁will 0.428955078125
▁rely 5.68359375
▁on 0.362060546875
▁efficient 3.63671875
▁supply 2.2265625
▁ch 1.0869140625
ains 0.00018155574798583984
▁and 0.63916015625
▁partners 4.296875
hips 0.0254364013671875
▁with 0.272216796875
▁ph 1.533203125
arma 0.0247955322265625
ce 0.11077880859375
ut 3.814697265625e-06
ical 4.4465065002441406e-05
▁companies 0.69970703125
▁to 3.05859375
▁ensure 1.6484375
▁access 3.0703125
ibility 0.552734375
▁and 1.2001953125
▁afford 0.66552734375
ability 0.007183074951171875
▁for 2.1640625
▁patients 0.436279296875
▁glob 4.265625
ally 3.2782554626464844e-05
. 0.0085296630859375
<0x0A> 0.239013671875
Des 3.1640625
p 0.007785797119140625
ite 0.00018584728240966797
▁the 1.5595703125
▁hur 2.68359375
d 4.649162292480469e-06
les 0.0027179718017578125
▁British 1.267578125
▁Bi 0.0038204193115234375
ote 8.296966552734375e-05
ch 0.005435943603515625
▁faces 1.0517578125
, 0.75048828125
▁hopes 10.4921875
▁remain 1.0986328125
▁high 0.6728515625
▁for 0.4228515625
▁Mar 2.576171875
im 0.00102996826171875
ast 0.004741668701171875
at 0.0004470348358154297
' 0.57080078125
s 0.00035834312438964844
▁block 6.328125
b 0.0009388923645019531
uster 0.002841949462890625
▁potential 0.27734375
. 0.174072265625
▁The 0.65771484375
▁drug 1.1376953125
' 1.1943359375
s 0.00011813640594482422
▁effic 3.115234375
acy 1.9550323486328125e-05
▁in 2.33984375
▁early 3.84375
▁clin 0.1800537109375
ical 0.00018680095672607422
▁tri 0.03271484375
als 2.5033950805664062e-06
, 2.732421875
▁couple 1.4658203125
d 0.00019168853759765625
▁with 0.002079010009765625
▁on 4.9375
going 0.01331329345703125
▁research 1.55078125
▁and 0.7490234375
▁development 0.28515625
▁efforts 1.287109375
, 0.07904052734375
▁show 4.1640625
cases 7.15625
▁British 2.728515625
▁Bi 0.0029964447021484375
ote 6.54458999633789e-05
ch 0.002925872802734375
' 0.048004150390625
s 0.00031638145446777344
▁commit 1.8935546875
ment 0.00047016143798828125
▁to 0.0282135009765625
▁adv 2.7578125
ancing 0.035797119140625
▁cancer 3.078125
▁treatment 1.0126953125
. 1.2744140625
▁The 1.154296875
▁company 0.36279296875
' 0.92578125
s 3.349781036376953e-05
▁determ 3.6953125
ination 8.189678192138672e-05
▁to 0.275634765625
▁overcome 2.236328125
▁regul 2.669921875
atory 0.0011997222900390625
▁requirements 5.859375
, 2.08203125
▁address 3.123046875
▁potential 2.134765625
▁side 0.2431640625
▁effects 0.004116058349609375
, 0.0966796875
▁demonstrate 6.8203125
▁superior 3.396484375
ity 0.108642578125
▁over 0.1995849609375
▁existing 0.7392578125
▁ther 0.931640625
ap 0.0016508102416992188
ies 1.1920928955078125e-06
▁and 3.47265625
▁establish 1.384765625
▁a 2.916015625
▁solid 4.484375
▁market 1.708984375
▁presence 1.03515625
▁all 4.5625
▁contribute 1.90625
▁to 0.024383544921875
▁the 1.3076171875
▁world 9.5859375
' 1.0908203125
s 0.00017380714416503906
▁eager 8.03125
▁anticip 0.45068359375
ation 0.0016269683837890625
▁of 2.05078125
▁Mar 0.8154296875
im 0.0002620220184326172
ast 0.00433349609375
at 0.00047898292541503906
' 0.12158203125
s 0.0005059242248535156
▁future 3.26171875
▁success 1.330078125
. 0.100830078125
